Skip to main content

VALIDACION DE NUEVOS BIOMARCADORES DE REMODELADO VASCULAR PATOLOGICO IDENTIFICADOS POR ANALISIS PROTEOMICO MASIVO

PID2019-106814RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

  • Roldán-Montero, R
  • Pérez-Sáez, Juan M.
  • Cerro-Pardo, Isabel
  • Oller, Jorge
  • Martinez-Lopez, Diego
  • Nuñez, Estefania
  • Maller, Sebastian M.
  • Gutierrez-Muñoz, Carmen
  • Mendez-Barbero, Nerea
  • Escola-Gil, Joan C.
  • Michel, Jean-Baptiste
  • Mittelbrunn, Maria
  • Vázquez, Jesús
  • Blanco-Colio, Luis M.
  • Rabinovich, Gabriel A.
  • Martín-Ventura, Jose Luis
Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1-/-) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1-/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA., This study was funded by the Spanish MINECO (PID2019-106814RB-I00 and PGC2018-097019-B-I00), CAM (Complemento II-CM, S2017/BMD-3673), Fondo de Investigaciones Sanitarias ISCiii-FEDER [Biobancos RD09/0076/00101 and PRB3 (IPT17/0019, ProteoRed)], and FEDER “Una manera de hacer Europa.” CIBERCV and CIBERDEM are Instituto de Salud Carlos III projects. This work also received funding from “La Caixa” Banking Foundation under the project code HR17-00247. The CNIC is supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (MCNU), and Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Further support was provided by Santander-UAM, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (PICT 2010-870, Argentina), Fundación Sales, and Fundación Bunge y Born (Argentina). We thank the support of Ferioli, Ostry, and Caraballo families
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

  • Roldán-Montero, Raquel|||0000-0003-0117-2608
  • Pérez-Sáez, Juan M.|||0000-0002-6722-5760
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Oller Pedrosa, Jorge|||0000-0002-2224-2954
  • Martínez-López, Diego
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Maller, Sebastian M.|||0000-0001-5536-7596
  • Gutiérrez Muñoz, Carmen|||0000-0001-8975-6135
  • Mendez-Barbero, Nerea|||0000-0003-1620-3067
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Michel, Jean-Baptiste
  • Mittelbrunn, Maria|||0000-0003-3487-8762
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Rabinovich, Gabriel A.|||0000-0002-0947-8735
  • Martin-Ventura, Jose L.|||0000-0003-2090-8641
Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1 -/- ) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1 -/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA. Galectin-1 plays an essential role in prevention of atherosclerosis and abdominal aortic aneurysm.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm

  • Rodríguez-Carrio, J.
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Lindholt, Jes S.|||0000-0001-9536-4488
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Martínez-López, Diego
  • Roldán-Montero, R.
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Michel, J.B.
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Suárez, A.
  • Martín-Ventura, J.L.
High Density Lipoprotein (HDL) plays a protective role in abdominal aortic aneurysm (AAA); however, recent findings suggest that oxidative modifications could lead to dysfunctional HDL in AAA. This study aimed at testing the effect of oxidized HDL on aortic lesions and humoral immune responses in a mouse model of AAA induced by elastase, and evaluating whether antibodies against modified HDL can be found in AAA patients. HDL particles were oxidized with malondialdehyde (HDL-MDA) and the changes were studied by biochemical and proteomics approaches. Experimental AAA was induced in mice by elastase perfusion and then mice were treated with HDL-MDA, HDL or vehicle for 14 days. Aortic lesions were studied by histomorphometric analysis. Levels of anti-HDL-MDA IgG antibodies were measured by an in-house immunoassay in the mouse model, in human tissue-supernatants and in plasma samples from the VIVA cohort. HDL oxidation with MDA was confirmed by enhanced susceptibility to diene formation. Proteomics demonstrated the presence of MDA adducts on Lysine residues of HDL proteins, mainly ApoA-I. MDA-modification of HDL abrogated the protective effect of HDL on cultured endothelial cells as well as on AAA dilation in mice. Exposure to HDL-MDA elicited an anti-HDL-MDA IgG response in mice. Anti-HDL-MDA were also detected in tissue-conditioned media from AAA patients, mainly in intraluminal thrombus. Higher plasma levels of anti-HDL-MDA IgG antibodies were found in AAA patients compared to controls. Anti-HDL-MDA levels were associated with smoking and were independent predictors of overall mortality in AAA patients. Overall, MDA-oxidized HDL trigger a specific humoral immune response in mice. Besides, antibodies against HDL-MDA can be detected in tissue and plasma of AAA patients, suggesting its potential use as surrogate stable biomarkers of oxidative stress in AAA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of covid-19 and non-covid-19 pneumonia in down syndrome

  • Real de Asua, Diego
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Del Carmen Ortega, María
  • Borrel, Jose M.
  • de Jesús Bermejo, Teresa
  • González-lamuño, Domingo|||0000-0002-7578-241X
  • Manso, Coral
  • Moldenhauer, Fernando|||0000-0002-6259-8226
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Hüls, Anke|||0000-0002-6005-417X
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Dierssen, Mara|||0000-0003-0853-6865
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID- 19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

  • Nuñez, Estefania|||0000-0002-0876-1264
  • Fuster, Valentín
  • Gómez-Serrano, María
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Fernández-Alvira, Juan Miguel
  • Martínez-López, Diego
  • Rodríguez, José Manuel
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Calvo, Enrique
  • Alfayate, Alvaro
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Fernández-Friera, Leticia
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Mendiguren, José María
  • Sánchez-Cabo, Fátima|||0000-0003-1881-1664
  • Sanz Salvo, Javier
  • Ordovás, José María
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • García-Ruiz, José Manuel
  • Ibañez, Borja|||0000-0002-5036-254X
  • Lara-Pezzi, Enrique
  • Fernández-Ortiz, Antonio
  • Martín-Ventura, José Luis
  • Vázquez, Jesús|||0000-0003-1461-5092
Background: Imaging of subclinical atherosclerosis improves cardiovascular risk prediction on top of traditional risk factors. However, cardiovascular imaging is not universally available. This work aims to identify circulating proteins that could predict subclinical atherosclerosis. Methods: Hypothesis-free proteomics was used to analyze plasma from 444 subjects from PESA cohort study (222 with extensive atherosclerosis on imaging, and 222 matched controls) at two timepoints (three years apart) for discovery, and from 350 subjects from AWHS cohort study (175 subjects with extensive atherosclerosis on imaging and 175 matched controls) for external validation. A selected three-protein panel was further validated by immunoturbidimetry in the AWHS population and in 2999 subjects from ILERVAS cohort study. Findings: PIGR, IGHA2, APOA, HPT and HEP2 were associated with subclinical atherosclerosis independently from traditional risk factors at both timepoints in the discovery and validation cohorts. Multivariate analysis rendered a potential three-protein biomarker panel, including IGHA2, APOA and HPT. Immunoturbidimetry confirmed the independent associations of these three proteins with subclinical atherosclerosis in AWHS and ILERVAS. A machine-learning model with these three proteins was able to predict subclinical atherosclerosis in ILERVAS (AUC [95%CI]:0.73 [0.70-0.74], p < 1 × 10), and also in the subpopulation of individuals with low cardiovascular risk according to FHS 10-year score (0.71 [0.69-0.73], p < 1 × 10). Interpretation: Plasma levels of IGHA2, APOA and HPT are associated with subclinical atherosclerosis independently of traditional risk factors and offers potential to predict this disease. The panel could improve primary prevention strategies in areas where imaging is not available.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Role of extracellular vesicles as potential diagnostic and/or therapeutic biomarkers in chronic cardiovascular diseases

  • Martín-Ventura, José Luis
  • Roncal Mancho, Carmen
  • Orbe, Josune
  • Blanco-Colio, Luis Miguel
Cardiovascular diseases (CVDs) are the first cause of death worldwide. In recent years, there has been great interest in the analysis of extracellular vesicles (EVs), including exosomes and microparticles, as potential mediators of biological communication between circulating cells/plasma and cells of the vasculature. Besides their activity as biological effectors, EVs have been also investigated as circulating/systemic biomarkers in different acute and chronic CVDs. In this review, the role of EVs as potential diagnostic and prognostic biomarkers in chronic cardiovascular diseases, including atherosclerosis (mainly, peripheral arterial disease, PAD), aortic stenosis (AS) and aortic aneurysms (AAs), will be described. Mechanistically, we will analyze the implication of EVs in pathological processes associated to cardiovascular remodeling, with special emphasis in their role in vascular and valvular calcification. Specifically, we will focus on the participation of EVs in calcium accumulation in the pathological vascular wall and aortic valves, involving the phenotypic change of vascular smooth muscle cells (SMCs) or valvular interstitial cells (IC) to osteoblast-like cells. The knowledge of the implication of EVs in the pathogenic mechanisms of cardiovascular remodeling is still to be completely deciphered but there are promising results supporting their potential translational application to the diagnosis and therapy of different CVDs., This study was funded by the Spanish Ministry of Economy and Competitiveness (PID2019-106814RB-I00), Comunidad Autónoma de Madrid (Complemento II-CM, S2017/BMD-3673), Instituto de Salud Carlos III (ISCiii-FEDER) (IPT17/0019, PI18/01195, PI19/00065 PI19/00128, and RD21/0006/0008) co-funded by European Regional Development Fund “A way to make Europe (ISCiii-FEDER), Spanish Biomedical Research Centre in Cardiovascular Disease (CB16/11/00371 and CB16/11/00333), The Foundation for Applied Medical Research, Universidad de Navarra (Spain) and La Caixa” Banking Foundation (HR17-00247).